ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform, Bolstering Oncology Portfolio
TL;DR
ABVC BioPharma's licensing deal with OncoX could yield up to $105 million, showcasing a strategic move to capitalize on the booming oncology market.
ABVC's affiliate OncoX acquires Lycogen® platform for $4.06 million, aiming to develop oncology treatments with a projected $25-30 million revenue over five years.
The acquisition of Lycogen® by OncoX, under ABVC's strategy, promises advancements in oncology treatments, potentially improving patient outcomes worldwide.
Lycogen®, a next-gen lycopene-analog, joins OncoX's pipeline, highlighting ABVC's innovative approach to leveraging natural compounds for cancer therapy.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced that its affiliate, OncoX BioPharma Inc., has acquired full ownership of the Lycopenoid Lycogen® platform. This acquisition, valued at approximately USD $4.06 million, includes patented manufacturing technology and commercialization rights from Asia-Pacific Biotech Developing Inc. (APBDI). The Lycogen® platform, known for its next-generation lycopene-analog produced by microbial fermentation, has shown preclinical promise in cancer-related and metabolic disease models due to its potent antioxidant and anti-inflammatory properties.
The strategic acquisition is expected to unlock significant commercial potential for OncoX across dermatology, oncology, and nutraceutical sectors. Internal forecasts suggest that cumulative revenue over the next five years could approach USD $25–30 million, with a portion of these revenues flowing back to ABVC through royalty payments. This exemplifies ABVC's strategy of leveraging affiliate-driven development for non-dilutive revenue growth.
Dr. Uttam Patil, ABVC Chief Executive Officer, highlighted the transaction as a testament to ABVC Group's position in botanical oncology innovation and its ability to convert platform assets into monetizable growth. The global oncology drug market, which exceeded USD $208 billion in 2023, is projected to grow to $484 billion by 2032, indicating a significant opportunity for ABVC and OncoX in this expanding market.
This acquisition not only strengthens OncoX's commercialization capability but also reflects ABVC's long-term growth strategy of utilizing platform assets to drive clinical value and generate shareholder return through tiered partnerships. The deal underscores the growing demand for multifunctional natural compounds in therapeutic and consumer applications, positioning ABVC and OncoX at the forefront of botanical oncology innovation.
Curated from NewMediaWire
